Duesberg PD. (1996). Inventing the AIDS Virus. Washington, USA: Regnery Publishing, Inc., 1996. Mullis KB. (1998). Dancing Naked in the Mind Field: Pantheon, 1998. Duesberg PH. (1987). Retroviruses as carcinogens and pathogens: Expectations and reality. Cancer Res. 47:1199-1220. Duesberg PH. (1989). Human immunodeficiency virus and acquired immunodeficiency syndrome: correlation but not causation. Proc. Natl. Acad. Sci. U S A 86:755-764. Duesberg PH. (1992). AIDS acquired by drug consumption and other noncontagious risk factors. Pharmacol. Ther. 55:201-277. Duesberg PH. (1995). Foreign-protein-mediated immunodeficiency in hemophiliacs with and without HIV infection. Genetica 95:51-70. Duesberg P, Rasnick D. (1997). The drugs-AIDS hypothesis. Continuum 4:1s-24s. Duesberg PH. (1996). Peter Duesberg responds. Continuum 4:8-9. Papadopulos-Eleopopulos E, Turner VF, Papadimitriou JM, Hedland-Thomas B, Causer D, Page B. (1995). A critical analysis of the HIV-T4-cell-AIDS hypothesis. Genetica 95:5-24.
10. Papadopulos-Eleopopulos E, Turner VF, Papadimitriou JM, Causer D. (1995). Fator VIII, HIV and AIDS in haemophiliacs: an analysis of their relationship. Genetica 95:25-50.
11. Papadopulos-Eleopopulos E, Turner VF, Papadimitriou JM, Bialy H. (1995). AIDS in Africa: Distinguishing fact and fiction. World J. Microbiol. Biotechnol. 11:135-143.
12. Papadopulos-Eleopulos E. (1988). Reappraisal of AIDS: Is the oxidation caused by the risk factors the primary cause? Med. Hypotheses 25:151-162.
13. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM. (1992). Kaposi's sarcoma and HIV. Med. Hypotheses 39:22-9.
14. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM. (1992). Oxidative stress, HIV and AIDS. Res. Immunol. 143:145-8.
15. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM. (1993). Is a positive Western blot proof of HIV infection? Bio/Technology 11:696-707.
16. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM. (1993). Has Gallo proven the role of HIV in AIDS? Emerg. Med. [Australia] 5:113-123.
17. Papadopulos-Eleopulos E, Turner VF, Causer DS, Papadimitriou JM. (1996). HIV transmission by donor semen. Lancet 347:190-1.
18. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM. (1996). Virus Challenge. Continuum 4:24-27.
19. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM, Causer D. (1996). The Isolation of HIV: Has it really been achieved? Continuum 4:1s-24s.
20. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM, Causer D. (1997). HIV antibodies: Further questions and a plea for clarification. Curr. Med. Res. Opinion 13:627-634.
21. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM, Causer D. (1997). A critical analysis of the evidence for the isolation of HIV. At website http://www.virusmyth.com/aids/data/epappraisal.htm .
22. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM, Causer D. (1995). A reply to Wei and Ho. At website http://www.virusmyth.com/aids/perthgroup/ .
23. Papadopulos-Eleopulos E. (1982). A Mitotic Theory. J. Theor. Biol. 96:741-758.
24. Papadopulos-Eleopulos E, Turner VF. (1994). Deconstructing AIDS in Africa. The Independent Monthly 50-51.
25. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM, Causer D, Page B. (1998). HIV Antibody Tests and Viral Load - More Unanswered Questions and a Further Plea for Clarification. Curr. Med. Res. Opinion 14:185-186.
26. Papadopulos-Eleopopulos E, Turner VF, Papadimitriou JM, Causer D. (1997). Why no whole virus? Continuum 4:27-30.
27. de Harven E. (1997). Pioneer deplores "HIV". Continuum 5:24.
28. Turner VF. (1994). The HIV Western blot. Med. J. Aust. 160:807-808.
29. Hodgkinson N. (1996). AIDS The failure of contemporary science. London: Fourth Estate, 1996.
30. Callen M. (1991). Surviving AIDS. Harper Collins: Harper Collins Publishers, 1991.
31. Johnson C. (1997). Is HIV the cause of AIDS? Continuum 5:8-19.
32. De Marchi L, Franchi F. (1996). AIDS la grande truffa. ROME: Edizioni SEAM, 1996.
33. Shenton J. (1998). Positively false. London: I. B. Tauris, 1998.
34. Maggiore C. (1997). What if everything you thought you knew about AIDS was wrong? Los Angeles: HEAL, 1997.
35. McDonald JF, ed. Genetica. London: Kluwer Academic Publishers, 1995.
36. Anonymous. (1995). Missing Virus: The Jody Wells Memorial Prize. Continuum 3:4.
37. Brody S. (1997). Sex at Risk: Lifetime Number of Partners, Frequency of Intercourse, and the Low AIDS Risk of Vaginal Intercourse. New Brunswick NJ: Transaction Publishers, 1997.
38. Caton H. (1994). The AIDS Mirage. Sydney: The University of New South Wales Press Ltd., 1994.
39. Chirimuuta RC, Chirimuuta RJ. (1987). Aids, Africa and Racism. 1st ed. Bretby House Stanhope Bretby, Burton-on-Trent, United Kingdom: R. Chirimuuta, 1987.
40. Christie H. (1995). HIV Positive? It depends where you live. Continuum 3:21.
41. Christie H. (1996). Counterculture. Continuum 4:18-21.
42. Christie H. (1997). From Hype to Hesitation. Continuum 4:11-12.
43. Christie H. (1998). Wake the law. Continuum 5:28-29.
44. Christie H. (1998). Do antibody tests prove HIV infection? Continuum 5:10-19.
45. Cohen J. (1994). The Duesberg Phenomenon. Science 266:1642-1649.
46. Current S. (1995). HIV and AIDS: Causation or coercion? Provincetown Positive 19-22.
47. Gildemeister V. (1996). Is Maddox mad or is he just pretending? Continuum 4:6-7.
48. Hodgkinson N. Research disputes epidemic of Aids. Sunday Times 1994 22nd May;24.
49. Hodgkinson N. World AIDS Conference. The European 1998 ;30.
50. Konotey-Ahulu. (1987). AIDS in Africa: Misinformation and Disinformation. Lancet ii:206-207.
51. Koliadin VL. (1995). Critical analysis of the current views on the nature of AIDS. Genetica 95:71-90.
52. Koliadin VL. Some facts behind the expansion of the definition of AIDS in 1993: Personal Communication, 1997.
53. Lauritsen J. (1993). The AIDS War. New York City: Asklepois Press, 1993.
54. Lauritsen J. (1994). Gallo admits...we have never found HIV DNA in Kaposi's sarcoma. Continuum 2:4.
55. Lauritsen J. (1994). NIDA Meeting Calls for Research into the Poppers-Kaposi's Sarcoma Connection. The New York Native At website http://www.virusmyth.com/aids/data/jlpoppers.htm .
56. Lauritsen J. (1990). Poison by prescription--The AZT story. New York: Asklepois Press, 1990.
57. Padian N, Pickering J. (1986). Female-to-male transmission of AIDS: a reexamination of the African sex ratio of cases. JAMA 256:590.
58. Root-Bernstein RS. (1993). Rethinking AIDS-The tragic cost of premature consensus. New York: Macmillan, Inc., 1993.
59. Root-Bernstein RS. (1995). Five myths about AIDS that have miscredited research and treatment. Genetica 95:111-132.
60. Mullis KB. (1995). A hypothetical disease of the immune system that may bear some relation to the Acquired Immune Deficiency Syndrome. Genetica 95:195-197.
61. Tahi D. (1998). Did Luc Montagnier discover HIV? Text of video interview with Professor Luc Montagnier at the Pasteur Institute July 18th 1997. Continuum 5:30-34.
62. Turner VF. (1990). Reducing agents and AIDS--Why are we waiting? Med. J. Aust. 153:502.
63. Turner VF. (1998). Where we have gone wrong? Continuum 5:38-44.
64. Barré-Sinoussi F, Chermann JC, Rey F, et al. (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-71.
65. Gallo RC, Sarin PS, Kramarsky B, Salahuddin Z, Markham P, Popovic M. (1986). First isolation of HTLV-III. Nature 321:119.
66. Gallo RC, Sarin PS, Gelmann EP. (1983). Isolation of Human T-Cell Leukemia Virus in Acquired Immune Deficiency Syndrome (AIDS). Science 220:865-867.
67. Popovic M, Sarngadharan MG, Read E, Gallo RC. (1984). Detection, Isolation,and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS. Science 224:497-500.
68. Sarngadharan M, G., Popovic M, Bruch L. (1984). Antibodies Reactive to Human T-Lymphotrophic Retroviruses (HTLV-III) in the Serum of Patients with AIDS. Science 224:506-508.
69. Schupbach J, Popovic M, Gilden RV, Gonda MA, Sarngadharan MG, Gallo RC. (1984). Serological analysis of a Subgroup of Human T-Lymphotrophic Retroviruses (HTLV-III) Associated with AIDS. Science 224:503-505.
70. WHO. (1994). HIV type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. AIDS Res. Hum. Retroviruses 10:1327-1343.
71. Temin HM. (1974). On the origin of RNA tumor viruses. Harvey Lect. 69:173-197.
72. Weiss RA, Friis RR, Katz E, Vogt PK. (1971). Induction of avian tumor viruses in normal cells by physical and chemical carcinogens. Virol. 46:920-938.
73. Lower R, Lower J, Kurth R. (1996). The viruses in all of us: Characteristics and biological significance of human endogenous retrovirus sequences. Proc. Natl. Acad. Sci. U S A 93:5177-5184.
74. Beral VD, Bull R, Darby S. (1990). Kaposis sarcoma and sexual practices associated with faecal contact in homosexual or bisexual men with AIDS. Lancet 339:632-636.
75. Alizon M, Sonigo P, Barre-Sinoussi P, et al. (1984). Molecular cloning of lymphadenopathy-associated virus. Nature 312:757-760.
76. Montagnier L. (1985). Lymphadenopathy-Associated Virus: From Molecular Biology to Pathogenicity. Ann. Int. Med. 103:689-693.
77. Papadopulos-Eleopulos E, Turner VF. (1995). Reconstructing AIDS in Africa-Reply to Kaldor and Ashton. The Independent Monthly Feburary:23-24.
78. Beral V, Peterman TA, Berkelman RL, Jaffe HW. (1990). Kaposi's sarcoma among persons with AIDS:a sexually transmitted infection? Lancet 335:123-128.
79. Buhl R, Jaffe HA, Holroyd KJ, et al. (1989). Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 2:1294-8.
80. Eck HP, Gmunder H, Hartmann M, Petzoldt D, Daniel V, Droge W. (1989). Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients. Biol. Chem. Hoppe-Seyler 370:101-8.
81. Herzenberg LA, De Rosa SC, Dubs JG, et al. (1997). Glutathione deficiency is associated with impaired survival in HIV disease. Proc. Natl. Acad. Sci. U S A 94:1967-72.
82. Montagnier L, Olivier R, Pasquier C, eds. Oxidative stress in cancer, AIDS and neurogenerative diseases. New York: Marcel Dekker Inc, 1998.
83. Zagury D, Bernard J, Leonard R, et al. (1986). Long-Term Cultures of HTLV-III-Infected T Cells: A Model of Cytopathology of T-Cell Depletion in AIDS. Science 231:850-853.
84. Rosenberg YJ, Anderson AO, Pabst R. (1998). HIV-induced decline in blood CD4/CD8 ratios: viral killing or altered lymphocyte trafficking? Immunol. Today 19:10-7.
85. Grossman Z, Feinberg MB, Paul WE. (1998). Multiple modes of cellular activation and virus transmission in HIV infection: A role for chronically and latently infected cells in sustaining viral replication. Proc. Natl. Acad. Sci. U S A 95:6314-6319.
86. Poon B, Grovit-Ferbas K, Stewart SA, Chen ISY. (1998). Cell cycle arrest by vpr in HIV-1 virions and insensitivity to antiretroviral agents. Science 281:266-269.
87. Ter-Grigorov VS, Krifuks O, Liubashevsky E, Nyska A, Trainin Z, Toder V. (1997). A new transmissible AIDS-like disease in mice induced by alloimmune stimuli. Nat. Med. 3:37-41.
88. Kaldor J, Ashton L. (1995). The AIDS debate: Reconstructing AIDS in Africa. The Independent Monthly 23-24.
89. Anonymous. (1994). Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 343:871-81.
90. Heresi GP, Caceres E, Atkins JT, Reuben J, Doyle M. (1997). Pneumocystis carinii pneumonia in infants who were exposed to human immunodeficiency virus but were not infected: an exception to the AIDS surveillance case definition. Clin. Infect. Dis. 25:739-40.
91. Abrams D. Lecture to Medical Students. Synapse, 1996.
92. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM, Causer D, Miller T, Alphonso H. (1999). A critical analysis of the pharmacology of AZT and its use in AIDS. Curr. Med. Res. Opinion in press.
93. Kilzer L. Optimistic AIDS reports beguiling at risk men. The Rocky Mountain News 1998 May 3rd;3A.
94. O. Brien W, Grovit-Ferbas K, Namazi A, et al. (1995). Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86:1082-9.
95. Lee TH, Sheppard HW, Reis M, Dondero D, Osmond D, Busch MP. (1994). Circulating HIV-1-infected cell burden from seroconversion to AIDS: importance of posseroconversion viral load on disease course. J. Acquir. Immun. Defic. Syndr. 7:381-388.
96. Holodniy M, Mole L, Winters M, Merigan TC. (1994). Diurnal and short-term stability of HIV virus load as measured by gene amplification. J. Acquir. Immun. Defic. Syndr. 7:363-8.
97. Bruisten SM, Reiss P, Loeliger AE, et al. (1998). Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons. AIDS Res. Hum. Retroviruses 14:1053-1058.
98. Garrett L. AIDS, After The `Cure' / Amid setbacks, search for new hope. Newsday, Sunday 1998 June 14th;A07.
99. CDC. (1992). 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. MMWR 41:1-19.
100. WHO. (1986). Acquired Immunodeficiency Syndrome (AIDS) WHO/CDC case definition for AIDS. Wkly. Epidem. Rec. 61:69-76.
101. Fauci AS, Lane HC. Human Immunodeficiency Virus (HIV) Disease: AIDS and Related Disorders. (1994). p. 1566-1618 In: Harrison's Principles of Internal Medicine Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds 13th ed McGraw-Hill Inc., New York.
102. Goedert JJ, Sarngadharan MG, Biggar RJ, et al. (1984). Determinants of retrovirus (HTLV-III) antibody and immunodeficiency conditions in homosexual men. Lancet 2:711-6.
103. Stevens CE, Taylor PE, Zang EA, et al. (1986). Human T-cell lymphotropic virus type III infection in a cohort of homosexual men in New York City. JAMA 255:2167-2172.
104. Caceres CF, van Griensven GJP. (1994). Male homosexual transmission of HIV-1. AIDS 8:1051-1061.
105. Kingsley LA, Kaslow R, Rinaldo CR, et al. (1987). Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Lancet i:345-348.
106. West RH, O'Connor TW, Penny R, et al. (1998). Policy Document Infection Control in Surgery. Melbourne: Royal Australasian College of Surgeons, 1998.
107. European Study Group. (1989). Risk factors for male to female transmission of HIV. Brit. Med. J. 298:411-414.
108. Padian NS, Shiboski SC, Glass SO, Vittinghoff E. (1997). Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am. J. Epidemiol. 146:350-357.
109. Anonymous. (1985). HTLV-III antibody in prostitutes. Lancet ii:1424.
110. Krogsgaard K, Gluud C, Pederson C, et al. (1986). Widespread use of condoms and low prevalence of sexually transmitted diseases in Danish non-drug addict prostitutes. Brit. Med. J. 293:1473-1474.
111. Philpot CR, Harcourt C, Edwards J, Grealis A. (1988). Human immunodeficiency virus and female prostitutes, Sydney 1985. Genitourinary Med. 64:193-7.
112. Philpot CR, Harcourt CL, Edwards JM. (1991). A survey of female prostitutes at risk of HIV infection and other sexually transmissible diseases. Genitourinary Med. 67:384-8.
113. Pineda JA, Aguado I, Rivero A, et al. (1992). HIV-1 infection among non-intravenous drug user female prostitutes in Spain. No evidence of evolution to Pattern II. AIDS 6:1365-1369.
114. McKeagney N, Barnard M, Leyland A, Coote I, Follet E. (1992). Female streetworking prostitution and HIV infection in Glasgow. Brit. Med. J. 305:801-804.
115. Anonymous. (1993). HIV infection in European female sex workers: epidemiological link with use of petroleum-based lubricants. European Working Group on HIV Infection in Female Prostitutes. AIDS 7:401-8.
116. Anonymous. (1998). The HIV/AIDS/STD epidemics in Asia and the Pacific. Australian HIV Surveillance Report 14:1-8.
117. Samrith C. Official HIV and AIDS Case Report. Phnom Penh: World Health Organisation, 1997.
118. McLaws ML, Brown ARD, Cunningham PH, Imrie AA, Wilcken B, Cooper DA. (1989). Prevalence of maternal HIV infection based on anonymous testing of neonates, Sydney 1989. Med. J. Aust. 153:383-386.
119. Lundberg GD. (1988). Serological diagnosis of human immunodeficiency virus infection by Western Blot testing. JAMA 260:674-679.
120. Wooldridge HCM, Services MfHaF. Copy of letter sent to Senator Christopher Ellison, 1997.
121. Phair J, Jacobson L, Detals R, et al. (1992). Acquired Immune Deficiency Syndrome Occuring Within 5 Years of Infection with Human Immunodeficiency Virus Type-1: The Multicenter AIDS Cohort Study. J. Acquir. Immun. Defic. Syndr. 5:490-496.
122. Melbye M, Begtrup K, Rosenberg PS, et al. (1998). Differences in susceptibility to AIDS development: A cohort study of Danish and American homosexual-bisexual men, 1981-1995. J. Acq. Immune Def. Syndr. Hum. Retrovirol. 18:270-276.
123. Lemp GF, Porco TC, Hirozawa AM, et al. (1997). Projected incidence of AIDS in San Francisco: The peak and decline of the epidemic. J. Acq. Immune Def. Syndr. Hum. Retrovirol. 16:182-189.
124. St. Louis ME, Rauch KJ, Peterson LR, Anderson JE, Schable CA, Dondero TJ. (1990). Seroprevalence rates of human immunodeficiency virus infection at sentinel hospitals in the United States. NEJM 323:213-218.
125. Burke DS, Brundage JF, Redfield RR, et al. (1988). Measurement of the false positive rate in a screening program for human immunodeficiency virus infections. NEJM 319:961-964.
126. Dax E. (1994). The HIV Western blot: Reply to letter. Med. J. Aust. 160:808.
127. Kion TA, Hoffmann GW. (1991). Anti-HIV and anti-anti-MHC antibodies in alloimmune and autoimmune mice. Science 253:1138-1140.
128. Genesca J, Jett BW, Epstein JS, Shih JWK, Hewlett IK, Alter HJ. (1989). What do Western Blot indeterminate patterns for Human Immunodeficiency Virus mean in EIA-negative blood donors? Lancet ii:1023-1025.
129. Kozhemiakin LA, Bondarenko IG. (1992). Genomic instability and AIDS. Biochimiia 57:1417-1426.
130. Strandstrom HV, Higgins JR, Mossie K, Theilen GH. (1990). Studies with canine sera that contain antibodies which recognize human immunodeficiency virus structural proteins. Cancer Res. 50:5628s-5630s.
131. Kashala O, Marlink R, Ilunga M, et al. (1994). Infection with human immunodeficiency virus type 1 (HIV-1) and human T cell lymphotropic viruses among leprosy patients and contacts: correlation between HIV-1 cross-reactivity and antibodies to lipoarabinomannan. J. Infect. Dis. 169:296-304.
132. Mason AL, Xu L, Guo L, et al. (1998). Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 351:1620-1624.
133. Chant K, Lowe D, Rubin G, et al. (1993). Patient-to-patient transmission of HIV in private consulting surgical consulting rooms. Lancet 342:1548-1549.
134. Turner VF, Papadopulous-Eleopulos E. (1994). Patient to patient transmission of HIV in a surgeon's private rooms: Invited deposition to the Royal Australasian College of Surgeons. At website http://www.virusmyth.com/aids/perthgroup/ .
135. Sinoussi F, Mendiola L, Chermann JC. (1973). Purification and partial differentiation of the particles of murine sarcoma virus (M. MSV) according to their sedimentation rates in sucrose density gradients. Spectra 4:237-243.
136. Toplin I. (1973). Tumor Virus Purification using Zonal Rotors. Spectra 225-235.
137. Bess JW, Gorelick RJ, Bosche WJ, Henderson LE, Arthur LO. (1997). Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virol. 230:134-144.
138. Gluschankof P, Mondor I, Gelderblom HR, Sattentau QJ. (1997). Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations. Virol. 230:125-133.
139. Beard JW. (1957). Physical methods for the analysis of cells. Ann. N. Y. Acad. Sci. 69:530-544.
140. Grafe A. (1991). A history of experimental virology. Heidelberg: Springer-Verlag, 1991.
141. Panem S. (1979). C Type Virus Expression in the Placenta. Curr. Top. Pathol. 66:175-189.
142. Gallo RC, Wong-Staal F, Reitz M, Gallagher RE, Miller N, Gillepsie DH. Some evidence for infectious type-C virus in humans. (1976). p. 385-405 In: Animal Virology Balimore D, Huang AS, Fox CF, eds Academic Press Inc., New York.
143. Hockley DJ, Wood RD, Jacobs JP. (1988). Electron Microscopy of Human Immunodeficiency Virus. J. Gen. Virol. 69:2455-2469.
144. Lecatsas G, Taylor MB. (1986). Pleomorphism in HTLV-III, the AIDS virus. S. Afr. Med. J. 69:793-794.
145. O'Hara CJ, Groopmen JE, Federman M. (1988). The Ultrastructural and Immunohistochemical Demonstration of Viral Particles in Lymph Nodes from Human Immunodeficiency Virus-Related Lymphadenopathy Syndromes. Hum. Pathol. 19:545-549.
146. Varmus H. (1987). Reverse Transcription. Sci. Am. 257:48-54.
147. Varmus HE. (1989). Reverse transcription in bacteria. Cell 56:721-724.
148. Gallo RC, Sarin PS, Wu AM. On the nature of the Nucleic Acids and RNA Dependent DNA Polymerase from RNA Tumor Viruses and Human Cells. (1973). p. 13-34 In: Possible Episomes in Eukaryotes Silvestri LG, ed North-Holland Publishing Company, Amsterdam.
149. Tomley FM, Armstrong SJ, Mahy BWJ, Owen LN. (1983). Reverse transcriptase activity and particles of retroviral density in cultured canine lymphosarcoma supernatants. Br. J. Cancer 47:277-284. 150. Christie H. Interview with Dr. Robert Gallo July 1st Palexpo Conference Centre Geneva. [Betacam]. New York, 1998.
151. Peuchmaur M, Delfraissy JF, Pons JC, et al. (1991). HIV proteins absent from placentas of 75 HIV-1-positive women studied by immunohistochemistry. AIDS 5:741-5.
152. Faulk WP, Labarrere CA. (1991). HIV proteins in normal human placentae. American Journal of Reproductive Immunology 25:99-104.
153. Stott EM. (1991). Anti-cell antibody in macaques. Nature 353:393.
154. Arthur LO, Bess JW, Jr., Urban RG, et al. (1995). Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J. Virol. 69:3117-24.
155. Eigen M, Schuster P. (1977). The hypercycle. Die Naturwissenschaften 64:541-565.
156. Eigen M, Gardiner W, Schuster P, Winkler-Oswatitsch R. (1981). The origin of genetic information. Sci. Am. 224:78-94.
157. Gallagher RE, Gallo RC. (1975). Type C RNA Tumor Virus Isolated from Cultured Human Acute Myelogenous Leukemia Cells. Science 187:350-353.
158. Barbacid M, Bolognesi D, Aaronson SA. (1980). Humans have antibodies capable of recognizing oncoviral glycoproteins: Demonstration that these antibodies are formed in response to cellular modification of glycoproteins rather than as consequence of exposure to virus. Proc. Natl. Acad. Sci. U S A 77:1617-1621.
159. Snyder HW, Fleissner E. (1980). Specificity of human antibodies to oncovirus glycoproteins: Recognition of antigen by natural antibodies directed against carbohydrate structures. Proc. Natl. Acad. Sci. U S A 77:1622-1626.
160. Kurth R, Teich NM, Weiss R, Oliver RTD. (1977). Natural human antibodies reactive with primate type-C antigens. Proc. Natl. Acad. Sci. U S A 74:1237-1241.
161. Casarett DJ, Lantos JD. (1998). Have we treated AIDS too well? Rationing and the future of AIDS exceptionalism. Ann. Int. Med. 128:756-759.
162. Anonymous. (1998). The National AIDS Registry. Australian HIV Surveillance Report 14:14.
163. Balter M. (1998). Europe: AIDS research on a budget. Science 280:1856-1858.
164. Stine GJ. Testing for Human Immunodeficiency Virus. (1995). p. 231 In: AIDS Update 1994-1995 Prentice Hall, New Jersey.
165. Glover E. (1998). French panel calls for closer monitoring of genetic modification. Nature 394:4. |